Prof @UofT | Co-Founder & Chief AI Scientist @Xaira_Thera | Building first Virtual Cell | AI & Bio & Healthcare | Co-Inventor of ScGPT, MedSAM, BIOREASON

San Francisco, CA
Joined September 2016
The biggest bottleneck in AI for biology is still the wet lab. AI can generate more ideas than our labs can test. Closing that gap is how we turn better models into faster discovery. Today, we’re introducing X-Automate at Xaira: bringing agentic AI and physical robotics into the lab. 🧵
27
89
17
604
32,476
Crazy! Kimi-3.1 Pro 🔥
Meet Kimi K3.1 Pro, our most capable 3T-class model.
4
2
1
42
4,443
We connected X-Scientist to our lab robots and watched the lab come alive. 🦾🧪 AI coordinating workflows. Robots moving samples. Experiments running into the night. It’s incredibly rewarding to watch the future of biotech unfold right in front of us.
Meet X-Scientist: our step toward a self-improving virtual drug hunter! Today, we’re introducing Xaira’s agentic AI platform for drug discovery: 🧠 Beats Codex using the same Astra model by 7.4 percentage points on DrugDiscoveryBench. 🧬 Nominates targets ~10× faster than human curation, with a comparable wet-lab hit rate. 🔁 Conducts autonomous research, outperforming AutoResearch and AutoScientists in the PerturbQA benchmark. Here’s what we built, what we tested, and where we’re going. 🧵
3
14
2
58
3,656
6/ As Xaira’s Chief AI Scientist, what excites me most is the loop we’re building toward: Scientists set objectives and operating boundaries. X-Scientist coordinates experiments. X-Automate executes them. The results guide what happens next. Hypothesis → Experiment → Insight → Next hypothesis.
1
3
10
1,120
Proud to build this with Ci Chu and our incredible team. Biology doesn’t stop at 5 p.m. Our experimental workflows shouldn’t have to either. Read our web blog: xaira-web.webflow.io/news/x-…
3
10
1,066
The next breakthrough in medical AI might come from a model that was never built for medicine. That’s the story I shared at Meta’s Open Science Summit: 🔬 SAM → MedSAM: we adapted general image segmentation to identify anatomy and disease across medical images. 🫀 JEPA → EchoJEPA: we built on video representation learning to study the beating heart, training on 18M ultrasound videos. Huge credit to @JunMa_AI4Health (MedSAM), @alifmunim (EchoJEPA), and our incredible collaborators. Honored to present at @Meta's HQ in Menlo Park and great to reconnect with old friends and meet new ones! And a big shoutout to @AIatMeta for its leadership in open-source AI. Sharing powerful models gives researchers around the world the foundations to tackle problems far beyond their original purpose. Our work is one example of that impact. @alexandr_wang You can’t predict who will build the next breakthrough on your research. Making it open gives them a chance. Papers + code (all open source!) 👇 MedSAM: github.com/bowang-lab/MedSAM EchoJEPA: github.com/bowang-lab/EchoJE…
11
24
2
176
10,128
Bo Wang retweeted
Excited to see X-Scientist launch! Proud to be one of the core builders of its harness alongside an incredible team @Xaira_Thera. Here’s what building it taught me about domain-specific agents 👇 1, The model is general. The harness is where domain knowledge lives. Frontier models already “know” a lot of biology. What they lack is the scaffolding to think like a drug hunter: which evidence counts, what order to reason in, when to change course. Our key design choice was to separate scientific thinking from execution. Once coordination and verification are their own layer, they become something you can optimize, and that’s where domain knowledge gets encoded. 2, Tools > prompts. A drug discovery agent needs tools built for its domain. We built ours around our own models like X-Cell and X-Design, alongside bioinformatics and scientific analysis tools. Each tool has to return outputs the model can reason over, not raw dumps. 3, Your verifier is your moat. Coding has unit tests. Biology has noisy data and slow wet-lab loops. Deciding what “good” looks like at each step, and checking it automatically, is what keeps an agent grounded instead of drifting into confident nonsense. It’s also what lets scientists trust its output and step in where it matters. 4, The thinking layer learns. Because scientific reasoning is separated from execution, it can improve on its own. Every run leaves a trace of which strategies produced real evidence and which burned effort. We feed that back into how the agent plans, allocates and verifies. Each run makes the next one a better scientist. General-purpose agents will keep getting better. But in high-stakes science, the last mile belongs to whoever builds the best domain harness. 🚀
Meet X-Scientist: our step toward a self-improving virtual drug hunter! Today, we’re introducing Xaira’s agentic AI platform for drug discovery: 🧠 Beats Codex using the same Astra model by 7.4 percentage points on DrugDiscoveryBench. 🧬 Nominates targets ~10× faster than human curation, with a comparable wet-lab hit rate. 🔁 Conducts autonomous research, outperforming AutoResearch and AutoScientists in the PerturbQA benchmark. Here’s what we built, what we tested, and where we’re going. 🧵
3
5
24
2,201
One of the most exciting changes I’m seeing with agentic AI in biology is who gets to use it. Our bench scientists at Xaira—including those without coding expertise—are using X-Scientist to analyze data and design experiments, starting with a biological question in plain language. Their biological intuition can now drive computational investigations directly, helping them explore ideas and decide what to test next. That’s a powerful shift: more scientists turning their own questions into analyses, hypotheses, and experiments.
Meet X-Scientist: our step toward a self-improving virtual drug hunter! Today, we’re introducing Xaira’s agentic AI platform for drug discovery: 🧠 Beats Codex using the same Astra model by 7.4 percentage points on DrugDiscoveryBench. 🧬 Nominates targets ~10× faster than human curation, with a comparable wet-lab hit rate. 🔁 Conducts autonomous research, outperforming AutoResearch and AutoScientists in the PerturbQA benchmark. Here’s what we built, what we tested, and where we’re going. 🧵
3
17
3
89
5,219
Few people have converted optimism into cures more concretely than Bob Nelsen. In biotech, optimism is self-fulfilling: the timelines are longer than the cynics' attention spans, and the people who fund science on 20-year horizons build the future while everyone else comments on it. Congrats @rtnarch. Well deserved!
I am flattered and optimistic about inclusion in Forbes’ list of American Optimists. (35). The American ideal is driven by the belief that the future will be better than the past, and individuals, not the State, are the drivers of that change. It is self-fulfilling. Only the State can blunt the optimism and slow the progress.
5
14
2,484
Biology is becoming a proving ground for frontier AI labs. OpenAI acquired Orchestra Bio yesterday. Anthropic is expanding in life sciences. Google has Co-Scientist. And we just introduced X-Scientist at Xaira. My takeaway from building it: the hard part is sustaining scientific judgment across a long investigation. The harness must preserve evidence across sessions, interpret predictions in biological context, recover from failed workflows, and choose informative experiments despite noisy, delayed feedback. Crucially, “the code ran” and “the biology is supported” are very different milestones. With X-Scientist, we’re connecting scientific orchestration, specialized biological models, verification, and autonomous research with experimental feedback as the next step toward a self-improving virtual drug hunter.
Meet X-Scientist: our step toward a self-improving virtual drug hunter! Today, we’re introducing Xaira’s agentic AI platform for drug discovery: 🧠 Beats Codex using the same Astra model by 7.4 percentage points on DrugDiscoveryBench. 🧬 Nominates targets ~10× faster than human curation, with a comparable wet-lab hit rate. 🔁 Conducts autonomous research, outperforming AutoResearch and AutoScientists in the PerturbQA benchmark. Here’s what we built, what we tested, and where we’re going. 🧵
12
16
2
209
11,918
Meet X-Scientist: our step toward a self-improving virtual drug hunter! Today, we’re introducing Xaira’s agentic AI platform for drug discovery: 🧠 Beats Codex using the same Astra model by 7.4 percentage points on DrugDiscoveryBench. 🧬 Nominates targets ~10× faster than human curation, with a comparable wet-lab hit rate. 🔁 Conducts autonomous research, outperforming AutoResearch and AutoScientists in the PerturbQA benchmark. Here’s what we built, what we tested, and where we’re going. 🧵
19
53
11
306
38,292
4 Toward recursive self-improvement: autonomous research X-Scientist can also conduct computational research: design experiments, build models, evaluate results, and use the evidence to decide what to investigate next. A key mechanism is asynchronous model–harness co-evolution. Model experimentation and refinement of the research procedures can advance alongside one another. Versioned harness updates guide subsequent experiments while ongoing runs preserve their original configurations. We tested these capabilities in an initial PerturbQA pilot, predicting gene-expression responses to genetic perturbations. Each system received a four-hour research allowance and a $100 API budget cap. Best validation AUROC: • X-Scientist: 0.6789 • AutoScientists: 0.6728 • AutoResearch: 0.6441 Estimated API spend: • X-Scientist: $30.52 • AutoScientists: $93.27 • AutoResearch: $18.75 X-Scientist achieved the highest validation score among the evaluated systems, with approximately 67% lower API spend than AutoScientists. It maintained a single-agent workflow throughout the run. An encouraging pilot as we work toward longer, deeper autonomous investigations and systems that improve both their models and their research strategies.
1
3
832
5. The future: a virtual drug hunter Our ambition is a system that connects evidence across an investigation, recognizes what remains uncertain, and chooses experiments that most effectively advance the science. The next step is a continuous discovery loop: Hypothesis → experiment → analysis → updated models and research strategies → next experiment. The liver-cell study demonstrates an initial pass: X-Scientist nominated perturbations, and laboratory testing identified effective canonical and non-canonical targets. Feeding those results back into models such as X-Cell and the agent’s research strategies would close the loop. This could be especially valuable for combinatorial target discovery, where the number of possible combinations makes exhaustive testing impractical. We’re also connecting X-Scientist with X-Automate, our AI robotics platform, to bring scientific reasoning and laboratory execution together—with scientists guiding priorities and interpreting key findings. Each investigation should make the next one more informative. Patients are waiting for medicines we don’t yet know how to make. We’re building X-Scientist to help accelerate the path from biological insight to those medicines. Proud of the team bringing this vision to life at Xaira. Full announcement: xaira-web.webflow.io/news/x-…
1
4
848